AAPL - Apple Inc.
APGE
Apogee Therapeutics, Inc.
79.24
2 x 56.92
2 x 98.24
bid
ask
+
13.20
19.99%
2 @ 07:29 AM
80.00 +0.76 (0.96%)
Ytd 4.98%
1y 98.90%
76.17
day range
81.46
26.20
52 week range
84.56
Open 76.75 Prev Close 66.04 Low 76.17 High 81.46 Mkt Cap 5.46B
Vol 3.45M Avg Vol 961.79K EPS -4.22 P/E N/A Forward P/E -12.07
Beta 1.40 Short Ratio 9.70 Inst. Own 130.71% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning 05-11 50-d Avg 71.39 200-d Avg 55.53 1yr Est 104.33
Earning
Date For Estimate Reported Surprise surprise %
2026-05-11 2026-03 0 N/A N/A N/A
2026-03-02 2025-12 0 N/A N/A N/A
2025-11-10 2025-09 0 N/A 0.03 2.63%
2025-11-10 2025-09 0 N/A N/A N/A
2025-08-11 2025-06 0 N/A -0.1 -9.71%
2025-08-11 2025-06 0 N/A N/A N/A
Upgrade / Downgrade
Date Firm Action From To
2026-03-23 BTIG Upgrade Buy Buy
2026-03-18 Truist Securities Upgrade Hold
2026-03-16 BTIG Upgrade Buy Buy
2026-03-03 RBC Capital Upgrade Sector Perform Sector Perform
2026-03-03 Wedbush Upgrade Outperform Outperform
2026-01-22 RBC Capital Downgrade Outperform Sector Perform
Profile
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Insider Holder
Date Name Relation Quantity Description
2026-03-03 DAMBKOWSKI CARL Officer 209.77K Sale
2026-01-21 FAIRMOUNT FUNDS MANAGEMENT LLC Unknown 0.00 Sale
2026-03-01 HENDERSON JANE Chief Financial Officer 181.37K Sale
2026-03-10 HENDERSON MICHAEL THOMAS Chief Executive Officer 1.15M Sale
2024-12-11 MCKENNA MARK C Director 20.00K Purchase
Institution Ownership
Report Date Organization Position Value Percentage
2025-12-30 VR Adviser, LLC 8.49M 673.01M 12.22%
2025-12-30 FMR, LLC 8.23M 651.75M 11.84%
2025-12-30 Wellington Management Group, LLP 4.75M 376.12M 6.83%
2025-12-30 Blackrock Inc. 3.78M 299.84M 5.45%
2025-12-30 Vanguard Group Inc 2.86M 226.45M 4.11%
2025-12-30 T. Rowe Price Investment Management, Inc. 2.73M 216.52M 3.93%
Fund Ownership
Report Date Organization Position Value Percentage
2025-10-30 VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund 2.89M 229.34M 4.17%
2026-01-30 Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund 1.70M 134.45M 2.44%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 1.58M 124.92M 2.27%
2025-12-30 T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App 1.30M 103.14M 1.87%
2026-01-30 iShares Trust-iShares Russell 2000 ETF 918.24K 72.76M 1.32%
2026-01-30 SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF 840.21K 66.58M 1.21%